Eli Lilly
and Company v. Fresenius Kabi Nederland B.V., District Court The Hague, 19 June
2019, Case no. ECLI:NL:RBDHA:2019:6107
Contrary to the Court of Appeal in summary proceedings, and
contrary to various foreign decisions in parallel proceedings, the District
Court of the Hague rules in the case on the merits that the scope of protection
of Eli Lilly’s patent EP 1 313 508 (hereafter: EP 508), entitled ‘Combination
containing an antifolate and methylmalonic acid lowering agent’ is limited to
the use of pemetrexed disodium and that the pemetrexed tromethamine used by
Fresenius falls outside the scope of protection, as the claims are consciously
limited to pemetrexed disodium.….
English
High Court refuses to grant Pfizer Arrow declaration
Pfizer’s attempt to secure an Arrow declaration in relation
to its proposed launch of a cancer drug in Europe was shot down yesterday, June
20, by the English High Court. Pfizer was seeking an Arrow declaration (a
declaration that certain acts would have been obvious in light of the state of
the art at a particular date) for its proposed launch of a biosimilar
monoclonal antibody drug called Zirabev (bevacizumab), which is used to treat
various cancers in combination with other drugs….
Purdue Pharma Patent Suit Against
Collegium Survives Dismissal
· Purdue’s
right to sue would exhaust after first sale
· Questions
remained about first sale
An agreement
between Purdue Pharma L.P. and Assertio Therapeutics Inc. that
forbade Collegium NF LLC from selling Nucynta doesn’t actually prevent
Collegium from selling the pain-relief drug. The doctrine of patent exhaustion
allows Collegium to resell the drug after a licensed purchase from Assertio,
the U.S. District Court for the District of Delaware said June 19. But
questions remained as to whether Assertio transferred the drug’s title to
Collegium, preventing the court from dismissing the case…
Fed. Circ.'s Vimovo Ruling Harms
Innovation, Horizon Says
The Federal Circuit has heightened the standard for
patenting new drugs by requiring companies to prove that new inventions are
effective to satisfy written description requirements, Horizon Pharma and Nuvo
Pharmaceuticals said in a bid to get two patents for the pain reliever Vimovo
revived.…
AstraZeneca Settles Patent Suit on Copycat
Faslodex Cancer Drug
AstraZeneca settled a lawsuit in which it had accused three
companies of violating patents with a proposed generic version of Faslodex, an
injectable treatment for breast cancer.
• Sino
Biopharm’s Chia Tai Tianqing, Athenex, and The WhiteOak Group are blocked from
selling their copy of Faslodex “except as specifically authorized” in the
settlement agreement, according to consent judgment approved Friday in federal
court in Camden, New Jersey
• Faslodex
had U.S. sales of $537 million in 2018, 2.6% of AstraZeneca’s revenue,
according...
Momenta,
Amphastar settle generic Lovenox drug patent case
Amphastar Pharmaceuticals Inc on Wednesday said Momenta
Pharmaceuticals Inc and Novartis AG’s Sandoz unit will pay it $59.9 million to
resolve patent and antitrust lawsuits over their dueling generic versions of
the blood-thinner Lovenox. The settlement ends an appeal by Momenta and Sandoz
of a Boston federal jury’s 2017 verdict finding that a patent they claimed Amphastar
infringed was invalid, a decision that exposed them to losing $100 million that
they had posted as a bond earlier in the litigation.….
No comments:
Post a Comment